---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-010916"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2022-07-22T23:59:59+00:00"
generated_at: "2026-06-24T09:30:51.167188+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech CFO Robyn Hunter resigns; David Jin appointed CFO effective Aug 16

## Summary
- CFO Robyn Hunter steps down after 11 years to pursue external opportunities; transition support through year-end.
- David Jin, current VP of Corporate Development and interim CEO/CFO of subsidiary Avenue Therapeutics, named CFO.
- Jin previously held roles at Barings, Sorrento Therapeutics, and FBR & Co, involved in over $3.5B in transactions.
- Jin will continue as Head of Corporate Development and is eligible for standard executive compensation.

## SEC filing metadata
- accession: 0001558370-22-010916
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2022-07-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837022010916/0001558370-22-010916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837022010916/fbio-20220721x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-010916
- JSON: https://secwatch.observer/filing/0001558370-22-010916.json
- Plain text: https://secwatch.observer/filing/0001558370-22-010916.txt

## Key facts
- Executive change
  David Jin was appointed as Chief Financial Officer at Fortress Biotech, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: effective August 16, 2022, David Jin, 32, who has served as the Company’s Vice President of Corporate Development and the Interim Principal Executive Officer and Chief Operating Officer of the Company’s subsidiary Avenue Therapeutics, Inc. (“Avenue”), was appointed Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000155837022010916/0001558370-22-010916-index.htm
- Executive change
  Robyn Hunter resigned as Chief Financial Officer at Fortress Biotech, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On July 21, 2022, Robyn Hunter, the Chief Financial Officer of Fortress Biotech, Inc. (the “Company”), provided notice to the Company of her resignation. Ms. Hunter’s resignation will be effective August 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000155837022010916/0001558370-22-010916-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.